Ignite Creation Date:
2024-05-06 @ 4:04 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04866862
Status:
UNKNOWN
Last Update Posted:
2022-07-25
First Post:
2021-03-28
Brief Title:
Fruquitinib Combined With Camrelizumab in Non MSI-HdMMR Refractory Colorectal Cancer
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
The First Affiliated Hospital with Nanjing Medical University
Study Overview
Official Title:
A Single Arm Open Label Phase II Exploratory Study of Fruquitinib Combined With Camrelizumab in Non MSI-H dMMR Refractory Colorectal Cancer
Status:
UNKNOWN
Status Verified Date:
2022-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Limited agents are optional after standard first and second line treatment for mCRC Nowadays cancer therapy has entered the era of immunotherapy The approved cancer therapies include pembrolizumab and nivolumab but only for MSI-H patients 95 of non MSI-H dMMR patients with advanced colorectal cancer can not benefit from them Therefore the use of PD-1 PD-L1 monoclonal antibody in mCRC is greatly limited Our previous research showed that anti-PD-1 combined with Fruquintinib can significantly inhibit the growth of CRC in MSS mice At the same time a retrospective clinical study showed that patients with MSS CRC can benefit from Sintilimab combined with Fruquintinib Camrelizumab is PD-1 monoclonal antibody which has been approved for a variety of tumors The prospective clinical trial of Camrelizumab combined with Fruquintinib may bring new hope for the treatment of non MSI-H dMMR patients with mCRCThis study is aimed to explore the efficacy safety in advanced colorectal cancer failed to standard therapy in Chinese population
Detailed Description:
Our previous research showed that anti-PD-1 combined with Fruquintinib can significantly inhibit the growth of CRC in MSS mice At the same time a retrospective clinical study showed that patients with MSS CRC can benefit from Sintilimab combined with Fruquintinib Camrelizumab is PD-1 monoclonal antibody which has been approved for a variety of tumors The prospective clinical trial of Camrelizumab combined with Fruquintinib may bring new hope for the treatment of non MSI-H dMMR patients with mCRCThis study is aimed to explore the efficacy safety in advanced colorectal cancer failed to standard therapy in Chinese population
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None